0001232524-17-000113.txt : 20170512 0001232524-17-000113.hdr.sgml : 20170512 20170512191427 ACCESSION NUMBER: 0001232524-17-000113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170511 FILED AS OF DATE: 20170512 DATE AS OF CHANGE: 20170512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc CENTRAL INDEX KEY: 0001232524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981032470 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 353-1-634-7800 MAIL ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COZADD BRUCE C CENTRAL INDEX KEY: 0001193210 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33500 FILM NUMBER: 17840607 MAIL ADDRESS: STREET 1: C/O JAZZ PHARMACEUTICALS PLC STREET 2: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD CITY: DUBLIN L2 4 STATE: L2 ZIP: 00000 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2017-05-11 0 0001232524 Jazz Pharmaceuticals plc JAZZ 0001193210 COZADD BRUCE C 5TH FL, WATERLOO EXCHANGE WATERLOO RD DUBLIN 4 L2 IRELAND 1 1 0 0 Chairman & CEO Ordinary Shares 2017-05-11 4 S 0 12073 153.1694 D 296418 D Ordinary Shares 2017-05-11 4 S 0 17927 153.675 D 278491 D Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.5200 to $153.5150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.5200 to $154.0400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. By: /s/Peter A Christou, as attorney in fact For: Bruce C. Cozadd 2017-05-12